SVB Leerink Initiates Coverage On Arrowhead Pharmaceuticals with Underperform Rating, Announces $32 Price Target

SVB Leerink initiates coverage on Arrowhead Pharmaceuticals (NASDAQ:ARWR) with a Underperform rating and a $32 price target.

Benzinga · 01/21/2020 14:08

SVB Leerink initiates coverage on Arrowhead Pharmaceuticals (NASDAQ:ARWR) with a Underperform rating and a $32 price target.